文献速递浆细胞疾病

抑制SUMO化克服多发性骨髓瘤对蛋白酶体抑制剂的耐药

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
PubMed 文献 · Blood Adv · 2023-01-01

复发/难治性多发性骨髓瘤(MM)呈SUMO高状态,SUMO E1激活酶(SAE1/UBA2)高表达与总生存差相关;卡非佐米(CFZ)持续处理增强SUMO通路活性。SUMO E1激活酶抑制剂subasumstat(TAK-981)与CFZ在CFZ敏感和耐药MM细胞系中均显示协同作用,与TP53状态无关;联合治疗在原代MM细胞和2个鼠MM异种移植模型中有效,机制涉及增强基因毒性和蛋白毒性应激,凋亡诱导与脯氨酰异构酶PIN1活性相关。

要点

  • 复发/难治性MM呈SUMO高状态,SAE1/UBA2高表达与总生存差相关。
  • CFZ持续处理MM细胞系增强SUMO通路活性。
  • subasumstat与CFZ联合在CFZ敏感和耐药MM细胞系中协同,与TP53状态无关。

核心结论

  • 激活的SUMO化是多发性骨髓瘤的治疗靶点,联合SUMO/蛋白酶体抑制是治疗蛋白酶体抑制剂耐药MM的新型强效策略。

研究设计与样本

  • 研究采用MM细胞系、原代MM细胞和2个鼠MM异种移植模型进行体外和体内实验。

主要发现

  • 复发/难治性MM呈SUMO高状态,SUMO E1激活酶(SAE1/UBA2)高表达与总生存差相关。
  • CFZ持续处理MM细胞系增强SUMO通路活性。
  • subasumstat与CFZ在CFZ敏感和CFZ耐药MM细胞系中均显示协同,与TP53状态无关。
  • 联合治疗在原代MM细胞和2个鼠MM异种移植模型中有效。
  • subasumstat与CFZ联合增强基因毒性和蛋白毒性应激,凋亡诱导与脯氨酰异构酶PIN1活性相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proteasome inhibition is a highly effective treatment for multiple myeloma (MM). However, virtually all patients develop proteasome inhibitor resistance, which is associated with a poor prognosis. Hyperactive small ubiquitin-like modifier (SUMO) signaling is involved in both cancer pathogenesis and cancer progression. A state of increased SUMOylation has been associated with aggressive cancer biology. We found that relapsed/refractory MM is characterized by a SUMO-high state, and high expression of the SUMO E1-activating enzyme (SAE1/UBA2) is associated with poor overall survival. Consistently, continuous treatment of MM cell lines with carfilzomib (CFZ) enhanced SUMO pathway activity. Treatment of MM cell lines with the SUMO E1-activating enzyme inhibitor subasumstat (TAK-981) showed synergy with CFZ in both CFZ-sensitive and CFZ-resistant MM cell lines, irrespective of the TP53 state. Combination therapy was effective in primary MM cells and in 2 murine MM xenograft models. Mechanistically, combination treatment with subasumstat and CFZ enhanced genotoxic and proteotoxic stress, and induced apoptosis was associated with activity of the prolyl isomerase PIN1. In summary, our findings reveal activated SUMOylation as a therapeutic target in MM and point to combined SUMO/proteasome inhibition as a novel and potent strategy for the treatment of proteasome inhibitor-resistant MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Heynen GJJE, Baumgartner F, Heider M, et al. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma. Blood Adv. 2023. PMID: 35917568. doi:10.1182/bloodadvances.2022007875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。